SCHEMBL6489974

SCHEMBL6489974

Cc1cc2cc(NC(=O)C3CCC3)ccc2n1C(=O)c1c(F)cccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.43
TYK2 P29597 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
JAK1 P23458 1/20 0.43
MGLL Q99685 1/20 0.43
MALT1 Q9UDY8 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GAA P10253 2/20 0.41
MAPT P10636 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492402 0.98 NPSR1 (0.46) JAK2TYK2NPSR1JAK1MGLL
SCHEMBL6492666 0.97 NPSR1 (0.45) JAK2TYK2NPSR1MGLLMALT1
SCHEMBL6490688 0.96 MGLL (0.44) JAK2TYK2JAK1MGLLMALT1
SCHEMBL6480771 0.94 NPSR1 (0.46) NPSR1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL6492262 0.93 NPSR1 (0.47) JAK2TYK2NPSR1JAK1SMN1; SMN2
SCHEMBL6480722 0.92 NPSR1 (0.49) NPSR1SMN1; SMN2MAOAMAOBHSD17B10
SCHEMBL6480891 0.91 NPSR1 (0.50) JAK2TYK2NPSR1JAK1SMN1; SMN2
SCHEMBL6481059 0.90 NPSR1 (0.49) JAK2TYK2NPSR1SMN1; SMN2MAOA
SCHEMBL6489116 0.90 HSD17B10 (0.44) NPSR1JAK1MGLLSMN1; SMN2GAA
SCHEMBL6487994 0.89 MEN1 (0.46) JAK2TYK2NPSR1JAK1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 JAK2 160/4885TYK2 2201/4885NPSR1 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.